North America Companion Diagnostics Market Analysis, 2025–2035
The North America Companion Diagnostics Market is projected to witness sustained growth due to rising adoption of precision medicine, integration of next-generation sequencing technologies, and expanding clinical applications. Increased collaborations between biopharma and diagnostics firms, favorable regulatory landscapes, and investments in personalized healthcare are among the key factors driving the market. Notable advances in oncology, especially for targeted therapies, as well as emerging uses in neurology and infectious diseases, are further accelerating market expansion into new therapeutic areas. Innovation by leading companies is expected to enable robust revenue growth through 2035.
Latest Market Dynamics
Key Drivers
- Growing demand for personalized medicine driven by oncology therapeutics, with Roche Diagnostics launching new FDA-approved companion assays in early 2024.
- Advancement in next-generation sequencing (NGS) platforms, led by Thermo Fisher Scientific’s extended NGS portfolio and expanded clinical testing menus launched through H2 2024.
Key Trends
- Integration of artificial intelligence for biomarker discovery and diagnostics workflow automation, as exemplified by Illumina Inc.'s AI capabilities integrated into clinical genomic testing in 2024.
- Strategic collaborations between pharmaceutical and diagnostic companies, such as the recent partnership between Abbott Laboratories and major pharma players in June 2024 to co-develop novel companion diagnostic assays.
Key Opportunities
- Expansion into non-oncology indications, including neurology and autoimmune conditions, with new assays from Qiagen NV targeting neurological biomarkers introduced in May 2024.
- Growth of decentralized testing through commercial service providers and reference laboratories, with Guardant Health opening a new US-based outpost in July 2024 to streamline liquid biopsy diagnostics.
Key Challenges
- High cost and complexity of multi-marker and gene panel tests, cited in Foundation Medicine’s mid-2024 report outlining reimbursement and implementation hurdles for multiplex diagnostics.
- Regulatory uncertainties in approval pathways for emerging companion diagnostics, highlighted by the experience of Myriad Genetics in US-FDA and Health Canada’s evolving frameworks for complex tests in 2024.
Key Restraints
- Limited clinical utility data for newly launched companion diagnostics, with BioMerieux SA’s recent market study (June 2024) showing adoption gaps due to insufficient long-term evidence.
- Fragmented reimbursement policies across North American regions, as reported by Almac Group and ARUP Laboratories in July 2024, impeding broad-based market uptake.
North America Companion Diagnostics Market Share by Type (2025)
In 2025, the North America Companion Diagnostics Market continues to be dominated by assays, followed by kits and reagents. The increasing prevalence of targeted therapies and the need for validated biomarkers drive assay demand. Kits and reagents, essential for streamlined and rapid testing, hold significant market shares, while instruments and software/services also show growing presence as the industry moves toward integrated workflows and digital diagnostics. The strong emphasis on clinical utility and regulatory compliance fuels continued product innovation and portfolio diversification, allowing manufacturers to address a spectrum of testing needs in hospital and reference laboratory settings.
North America Companion Diagnostics Market Share by Applications (2025)
Oncology applications command the largest market share in North America's companion diagnostics landscape in 2025, reflecting the region’s focus on targeted cancer therapies and precision medicine. Infectious diseases represent the second-largest segment, driven by rising adoption of advanced diagnostic tests for pathogen detection and pandemic preparedness. Neurology and cardiology are fast-growing application areas, bolstered by increasing biomarker discovery and new assay launches. Autoimmune diseases and ‘others’ provide steady market contributions, further diversifying the application spectrum and supporting ongoing growth across therapeutic verticals.
North America Companion Diagnostics Market Revenue (2020-2035)
The North America Companion Diagnostics Market demonstrates a robust revenue trajectory from 2020 to 2035. After achieving a market size of $3,120 Million in 2025, projections indicate consistent double-digit CAGR, propelled by innovations in molecular diagnostics and the rapid integration of NGS-based assays. Annual revenue gains reflect increased payer acceptance, greater test volumes from expanded therapeutic indications, and widening access through commercial and hospital laboratories. The forecast underscores the vital contribution of the US, followed by Canada and Mexico, to the region’s sustained market growth.
North America Companion Diagnostics Market YoY Growth (2020-2035)
Year-over-year (YoY) growth for the North America Companion Diagnostics Market remains robust, with peak acceleration observed in the mid-2020s, supported by regulatory approvals and rapid uptake of new technological platforms. Growth moderates from the early 2030s as market maturity is reached, but a steady stream of innovation and expanding clinical use cases sustains healthy YoY gains through 2035.
North America Companion Diagnostics Market Regional Share (2025)
The US overwhelmingly leads the North America Companion Diagnostics Market in 2025, accounting for more than three-quarters of regional revenues due to its advanced healthcare infrastructure, robust reimbursement environment, and concentration of diagnostic innovation. Canada holds a significant share owing to growing investments in molecular diagnostics and supportive government initiatives. Mexico, while representing a smaller proportion, shows strong potential for future market expansion driven by increasing awareness and adoption of precision diagnostics.
Leading Market Players in North America Companion Diagnostics (2025)
Roche Diagnostics asserts its leadership in the North America Companion Diagnostics Market in 2025, bolstered by a broad portfolio and continual innovation in oncology and NGS-based diagnostics. Abbott Laboratories and Thermo Fisher Scientific also capture substantial market shares, leveraging advanced platforms and extensive clinical networks. Agilent Technologies and Qiagen NV round out the region’s top five, distinguished by their comprehensive companion diagnostic offerings and deep expertise in genomic and proteomic test development.
Companion Diagnostics Market—Buyer Share, North America (2025)
Hospital laboratories represent the primary buyers of companion diagnostics in North America for 2025, reflecting the centralization of advanced testing services in major clinical environments. Commercial service providers—including standalone diagnostic laboratories—continue to expand their market share, supported by rising test outsourcing and accessibility initiatives. Reference laboratories and academic medical centers maintain vital roles as both clinical and research testing hubs, while an ‘others’ category includes niche and fast-growing buyer segments.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 3120 |
| Regions | US, Canada, Mexico |
| Segments | By Type (Assays, Kits, Reagents, Instruments, Software & Services, Others); By Application (Oncology, Neurology, Infectious Diseases, Cardiology, Autoimmune Diseases, Others); By Distribution Channels (Hospital Laboratories, Commercial Service Providers, Reference Laboratories, Academic Medical Centers, Others); By Technology (Polymerase Chain Reaction, In-situ Hybridization, Immunohistochemistry, Next-generation Sequencing, Gene Sequencing, Others); By Organization Size (Small, Medium, Large) |
| Players | Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Agilent Technologies Inc., Qiagen NV, Illumina Inc., Danaher Corporation, BioMerieux SA, Myriad Genetics Inc., Siemens Healthineers AG, Almac Group, ARUP Laboratories, Guardant Health, Foundation Medicine, Invitae Corporation |
Key Recent Developments
- June 2024: Roche Diagnostics launched a new multiplex companion diagnostic assay for breast cancer approved by FDA, expanding precision oncology offerings.
- July 2024: Guardant Health opened a new reference laboratory in the US focused on liquid biopsy CDx offerings, increasing accessibility for non-invasive testing.
- August 2024: Abbott Laboratories announced a joint development agreement with a major pharmaceutical partner to accelerate biomarker-driven diagnostic test launches.
- June 2024: Illumina Inc. integrated artificial intelligence into its NGS platforms for faster and more accurate biomarker identification in CDx applications.
- July 2024: Qiagen NV debuted a next-generation companion assay for neurological biomarkers aimed at MS and Alzheimer’s, receiving expedited Health Canada approval.
